| Benjamin Andrew Kitt, DO | |
|
111 17th Ave E, Alexandria, MN 56308-5273 | |
| (320) 762-1511 | |
| (320) 762-6070 |
| Full Name | Benjamin Andrew Kitt |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 111 17th Ave E, Alexandria, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750776530 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 65106 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alomere Health | Alexandria, MN | Hospital |
| Humboldt General Hospital | Winnemucca, NV | Hospital |
| Sanford Medical Center Thief River Falls | Thief river falls, MN | Hospital |
| Carris Health - Redwood, Llc | Redwood falls, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Douglas County Hospital | 0648171413 | 101 |
| Winnemucca Emergency Physicians Llc | 2860434503 | 14 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Unity Family Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326234006 PECOS PAC ID: 9830003516 Enrollment ID: O20031117000732 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20031231000690 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Douglas County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164424305 PECOS PAC ID: 0648171413 Enrollment ID: O20040115000387 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Centracare Health System - Melrose |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1720045073 PECOS PAC ID: 1658270368 Enrollment ID: O20060504000839 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Unity Family Healthcare |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1780630939 PECOS PAC ID: 9830003516 Enrollment ID: O20061104000248 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Sanford Health Network North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386047355 PECOS PAC ID: 8022206663 Enrollment ID: O20180205002429 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Sanford Health Network North |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1043218753 PECOS PAC ID: 8022206663 Enrollment ID: O20180222001872 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Entity Name | Carris Health - Redwood Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265914048 PECOS PAC ID: 7911259619 Enrollment ID: O20181129001082 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Benjamin Andrew Kitt, DO 111 17th Ave E, Alexandria, MN 56308-3798 Ph: (320) 762-1511 | Benjamin Andrew Kitt, DO 111 17th Ave E, Alexandria, MN 56308-5273 Ph: (320) 762-1511 |
News Archive
ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
The Journal of Clinical Oncology has published the results of the largest prospective multicenter trial conducted of FDG-PET/CT in head and neck cancer, providing rigorous data about its performance.
The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine of Yeshiva University a five-year, $4.8 million grant to study the molecular mechanism that allows the Ebola virus to cause infection and spread in animals.
› Verified 6 days ago
Dr. Gregory Steven Gesell, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 17th Ave E, Alexandria, MN 56308 Phone: 320-762-1511 Fax: 320-762-6101 | |
Mitchell Gesell, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 17th Ave E, Alexandria, MN 56308 Phone: 320-762-1511 Fax: 320-762-6101 | |
David J. Odland, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1527 Broadway St, Alexandria, MN 56308 Phone: 320-762-0399 | |
Dr. Dane Jason Mitteness, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 17th Ave E, Alexandria, MN 56308 Phone: 320-762-1511 |